Haemonetics Co. (NYSE:HAE) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Haemonetics Co. (NYSE:HAE) have earned a consensus rating of “Moderate Buy” from the four brokerages that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $109.50.

HAE has been the subject of several recent research reports. Needham & Company LLC raised Haemonetics from a “hold” rating to a “buy” rating and set a $112.00 price objective for the company in a research report on Wednesday, June 12th. JMP Securities lifted their price target on Haemonetics from $115.00 to $125.00 and gave the stock a “market outperform” rating in a research report on Friday, May 10th. Barrington Research lifted their price target on Haemonetics from $105.00 to $107.00 and gave the stock an “outperform” rating in a research report on Friday, May 10th. Finally, StockNews.com lowered Haemonetics from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd.

Haemonetics Stock Performance

Shares of Haemonetics stock opened at $82.80 on Friday. The company has a current ratio of 2.56, a quick ratio of 1.50 and a debt-to-equity ratio of 0.83. The firm has a market capitalization of $4.22 billion, a P/E ratio of 36.16, a P/E/G ratio of 1.51 and a beta of 0.37. The business has a fifty day simple moving average of $88.90 and a two-hundred day simple moving average of $83.70. Haemonetics has a 12 month low of $70.74 and a 12 month high of $97.97.

Haemonetics (NYSE:HAE) last announced its quarterly earnings data on Thursday, May 9th. The medical instruments supplier reported $0.90 EPS for the quarter, beating the consensus estimate of $0.88 by $0.02. The business had revenue of $343.00 million during the quarter, compared to analyst estimates of $329.53 million. Haemonetics had a return on equity of 22.25% and a net margin of 8.98%. The company’s revenue for the quarter was up 12.7% on a year-over-year basis. During the same quarter last year, the firm posted $0.77 earnings per share. On average, equities analysts forecast that Haemonetics will post 4.57 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Haemonetics news, insider Stewart W. Strong sold 8,857 shares of the business’s stock in a transaction dated Wednesday, May 29th. The stock was sold at an average price of $87.53, for a total value of $775,253.21. Following the completion of the transaction, the insider now owns 18,196 shares of the company’s stock, valued at approximately $1,592,695.88. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other Haemonetics news, insider Stewart W. Strong sold 8,857 shares of the business’s stock in a transaction dated Wednesday, May 29th. The stock was sold at an average price of $87.53, for a total value of $775,253.21. Following the completion of the transaction, the insider now owns 18,196 shares of the company’s stock, valued at approximately $1,592,695.88. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Stewart W. Strong sold 733 shares of the business’s stock in a transaction dated Thursday, May 16th. The stock was sold at an average price of $96.04, for a total value of $70,397.32. Following the completion of the transaction, the insider now directly owns 15,608 shares of the company’s stock, valued at approximately $1,498,992.32. The disclosure for this sale can be found here. In the last 90 days, insiders sold 27,380 shares of company stock valued at $2,445,816. 1.80% of the stock is owned by insiders.

Institutional Investors Weigh In On Haemonetics

Large investors have recently made changes to their positions in the company. TFO Wealth Partners LLC grew its stake in shares of Haemonetics by 29,450.0% during the 4th quarter. TFO Wealth Partners LLC now owns 591 shares of the medical instruments supplier’s stock valued at $51,000 after purchasing an additional 589 shares during the period. Covestor Ltd grew its stake in shares of Haemonetics by 184.8% during the 1st quarter. Covestor Ltd now owns 675 shares of the medical instruments supplier’s stock valued at $58,000 after purchasing an additional 438 shares during the period. EntryPoint Capital LLC bought a new stake in shares of Haemonetics during the 1st quarter valued at about $86,000. Parkside Financial Bank & Trust grew its stake in shares of Haemonetics by 17.4% during the 4th quarter. Parkside Financial Bank & Trust now owns 1,054 shares of the medical instruments supplier’s stock valued at $90,000 after purchasing an additional 156 shares during the period. Finally, Headlands Technologies LLC bought a new stake in shares of Haemonetics during the 1st quarter valued at about $114,000. 99.67% of the stock is currently owned by institutional investors.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.